TY - JOUR
T1 - Low human papillomavirus prevalence in head and neck cancer
T2 - Results from two large case-control studies in high-incidence regions
AU - Ribeiro, Karina Braga
AU - Levi, José Eduardo
AU - Pawlita, Michael
AU - Koifman, Sérgio
AU - Matos, Elena
AU - Eluf-Neto, José
AU - Wunsch-Filho, Victor
AU - Curado, Maria Paula
AU - Shangina, Oxana
AU - Zaridze, David
AU - Szeszenia-Dabrowska, Neonila
AU - Lissowska, Jolanta
AU - Daudt, Alexander
AU - Menezes, Ana
AU - Bencko, Vladimir
AU - Mates, Dana
AU - Fernandez, Letícia
AU - Fabianova, Eleonora
AU - Gheit, Tarik
AU - Tommasino, Massimo
AU - Boffetta, Paolo
AU - Brennan, Paul
AU - Waterboer, Tim
N1 - Funding Information:
Karina Braga Ribeiro was supported by a Fellowship from the International Agency for Research on Cancer. These studies were supported by grants from the INCO Copernicus program (contract ERBIC15-CT96-0313 (central Europe) and contract IC18-CT97-0222 (Latin America)) and the Funda¸cão de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (contract 2001/01768-2).
PY - 2011/4
Y1 - 2011/4
N2 - Background: Recent studies support an important role for human papillomavirus (HPV) in a subgroup of head and neck squamous cell carcinomas (HNSCC). We have evaluated the HPV deoxyribonucleic acid (DNA) prevalence as well as the association between serological response to HPV infection and HNSCC in two distinct populations from Central Europe (CE) and Latin America (LA). Methods: Cases (n=2214) and controls (n=3319) were recruited from 1998 to 2003, using a similar protocol including questionnaire and blood sample collection. Tumour DNA from 196 fresh tissue biopsies was analysed for multiple HPV types followed by an HPV type-specific polymerase chain reaction (PCR) protocol towards the E7 gene from HPV 16. Using multiplex serology, serum samples were analysed for antibodies to 17 HPV types. Statistical analysis included the estimation of adjusted odds ratios (ORs) and the respective 95% confidence intervals (CIs). Results: HPV16 E7 DNA prevalence among cases was 3.1% (6/196), including 4.4% in the oropharynx (3/68), 3.8% in the hypopharynx/larynx (3/78) and 0% among 50 cases of oral cavity carcinomas. Positivity for both HPV16 E6 and E7 antibodies was associated with a very high risk of oropharyngeal cancer (OR=179, 95% CI 35.8-899) and hypopharyngeal/laryngeal cancer (OR=14.9, 95% CI 2.92-76.1).Conclusions: A very low prevalence of HPV DNA and serum antibodies was observed among cases in both CE and LA. The proportion of head and neck cancer caused by HPV may vary substantially between different geographical regions and studies that are designed to evaluate the impact of HPV vaccination on HNSCC need to consider this heterogeneity. Published by Oxford University Press on behalf of the International Epidemiological Association
AB - Background: Recent studies support an important role for human papillomavirus (HPV) in a subgroup of head and neck squamous cell carcinomas (HNSCC). We have evaluated the HPV deoxyribonucleic acid (DNA) prevalence as well as the association between serological response to HPV infection and HNSCC in two distinct populations from Central Europe (CE) and Latin America (LA). Methods: Cases (n=2214) and controls (n=3319) were recruited from 1998 to 2003, using a similar protocol including questionnaire and blood sample collection. Tumour DNA from 196 fresh tissue biopsies was analysed for multiple HPV types followed by an HPV type-specific polymerase chain reaction (PCR) protocol towards the E7 gene from HPV 16. Using multiplex serology, serum samples were analysed for antibodies to 17 HPV types. Statistical analysis included the estimation of adjusted odds ratios (ORs) and the respective 95% confidence intervals (CIs). Results: HPV16 E7 DNA prevalence among cases was 3.1% (6/196), including 4.4% in the oropharynx (3/68), 3.8% in the hypopharynx/larynx (3/78) and 0% among 50 cases of oral cavity carcinomas. Positivity for both HPV16 E6 and E7 antibodies was associated with a very high risk of oropharyngeal cancer (OR=179, 95% CI 35.8-899) and hypopharyngeal/laryngeal cancer (OR=14.9, 95% CI 2.92-76.1).Conclusions: A very low prevalence of HPV DNA and serum antibodies was observed among cases in both CE and LA. The proportion of head and neck cancer caused by HPV may vary substantially between different geographical regions and studies that are designed to evaluate the impact of HPV vaccination on HNSCC need to consider this heterogeneity. Published by Oxford University Press on behalf of the International Epidemiological Association
KW - Central Europe
KW - Head and neck cancer
KW - Human papillomavirus (HPV)
KW - Latin America
UR - https://www.scopus.com/pages/publications/79953717110
U2 - 10.1093/ije/dyq249
DO - 10.1093/ije/dyq249
M3 - Article
C2 - 21224273
AN - SCOPUS:79953717110
SN - 0300-5771
VL - 40
SP - 489
EP - 502
JO - International Journal of Epidemiology
JF - International Journal of Epidemiology
IS - 2
M1 - dyq249
ER -